Search

Your search keyword '"Rossoni, Caroline"' showing total 20 results
Start Over Author "Rossoni, Caroline"
20 results on '"Rossoni, Caroline"'

1. Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer

Author

Nguyen Van Long, Flora, Lardy-Cleaud, Audrey, Carène, Dimitri, Rossoni, Caroline, Catez, Frédéric, Rollet, Paul, Pion, Nathalie, Monchiet, Déborah, Dolbeau, Agathe, Martin, Marjorie, Simioni, Valentin, Bray, Susan, Le Beherec, Doris, Mosele, Fernanda, Bouakka, Ibrahim, Colombe-Vermorel, Amélie, Odeyer, Laetitia, Diot, Alexandra, Jordan, Lee B., Thompson, Alastair M., Jamen, Françoise, Dubois, Thierry, Chabaud, Sylvie, Michiels, Stefan, Treilleux, Isabelle, Bourdon, Jean-Christophe, Pérol, David, Puisieux, Alain, André, Fabrice, Diaz, Jean-Jacques, and Marcel, Virginie

Published
2022
Full Text
View/download PDF

2. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

Author

Mezquita, Laura, Preeshagul, Isabel, Auclin, Edouard, Saravia, Diana, Hendriks, Lizza, Rizvi, Hira, Park, Wungki, Nadal, Ernest, Martin-Romano, Patricia, Ruffinelli, Jose C., Ponce, Santiago, Audigier-Valette, Clarisse, Carnio, Simona, Blanc-Durand, Felix, Bironzo, Paolo, Tabbò, Fabrizio, Reale, Maria Lucia, Novello, Silvia, Hellmann, Matthew D., Sawan, Peter, Girshman, Jeffrey, Plodkowski, Andrew J., Zalcman, Gerard, Majem, Margarita, Charrier, Melinda, Naigeon, Marie, Rossoni, Caroline, Mariniello, AnnaPaola, Paz-Ares, Luis, Dingemans, Anne Marie, Planchard, David, Cozic, Nathalie, Cassard, Lydie, Lopes, Gilberto, Chaput, Nathalie, Arbour, Kathryn, and Besse, Benjamin

Published
2021
Full Text
View/download PDF

3. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non–small cell lung cancer treated with immunotherapy

Author

Gataa, Ithar, Mezquita, Laura, Rossoni, Caroline, Auclin, Edouard, Kossai, Myriam, Aboubakar, Frank, Le Moulec, Sylvestre, Massé, Julie, Masson, Morgane, Radosevic-Robin, Nina, Alemany, Pierre, Rouanne, Mathieu, Bluthgen, Virginia, Hendriks, Lizza, Caramella, Caroline, Gazzah, Anas, Planchard, David, Pignon, Jean-Pierre, Besse, Benjamin, and Adam, Julien

Published
2021
Full Text
View/download PDF

4. Prospective Multicenter Study Validate a Prediction Model for Surgery Uptake Among Women with Atypical Breast Lesions

Author

Uzan, Catherine, Mazouni, Chafika, Rossoni, Caroline, De Korvin, Brigitte, de Lara, Christine Tunon, Cohen, Monique, Chabbert, Nathalie, Zilberman, Sonia, Boussion, Veronique, Vincent Salomon, Anne, Espie, Marc, Coutant, Charles, Marchal, Frederic, Salviat, Flore, Boulanger, Loic, Doutriaux-Dumoulin, Isabelle, Jouve, Eva, Mathelin, Carole, de Saint hilaire, Pierre, Mollard, Joelle, Balleyguier, Corinne, Joyon, Natacha, Triki, Magali Lacroix, Delaloge, Suzette, and Michiels, Stefan

Published
2021
Full Text
View/download PDF

8. A Randomised, Controlled Trial: Effect of a Multi-Strain Fermented Milk on the Gut Microbiota Recovery after Helicobacter pylori Therapy

Author

Guillemard, Eric, primary, Poirel, Marion, additional, Schäfer, Florent, additional, Quinquis, Laurent, additional, Rossoni, Caroline, additional, Keicher, Christian, additional, Wagner, Frank, additional, Szajewska, Hania, additional, Barbut, Frédéric, additional, Derrien, Muriel, additional, and Malfertheiner, Peter, additional

Published
2021
Full Text
View/download PDF

9. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.

Author

UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Gataa, Ithar, Mezquita, Laura, Rossoni, Caroline, Auclin, Edouard, Kossai, Myriam, Aboubakar Nana, Frank, Le Moulec, Sylvestre, Massé, Julie, Masson, Morgane, Radosevic-Robin, Nina, Alemany, Pierre, Rouanne, Mathieu, Bluthgen, Virginia, Hendriks, Lizza, Caramella, Caroline, Gazzah, Anas, Planchard, David, Pignon, Jean-Pierre, Besse, Benjamin, Adam, Julien, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Gataa, Ithar, Mezquita, Laura, Rossoni, Caroline, Auclin, Edouard, Kossai, Myriam, Aboubakar Nana, Frank, Le Moulec, Sylvestre, Massé, Julie, Masson, Morgane, Radosevic-Robin, Nina, Alemany, Pierre, Rouanne, Mathieu, Bluthgen, Virginia, Hendriks, Lizza, Caramella, Caroline, Gazzah, Anas, Planchard, David, Pignon, Jean-Pierre, Besse, Benjamin, and Adam, Julien

Abstract

BACKGROUND: The established role of morphological evaluation of tumour-infiltrating lymphocytes (TILs) with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) is unknown. We aimed to determine TIL association with the outcome for ICIs and for chemotherapy in advanced NSCLC. METHODS: This is a multicenter retrospective study of a nivolumab cohort of 221 patients treated between November 2012 and February 2017 and a chemotherapy cohort of 189 patients treated between June 2009 and October 2016. Patients with available tissue for stromal TIL evaluation were analysed. The presence of a high TIL count (high-TIL) was defined as ≥10% density. The primary end-point was overall survival (OS). RESULTS: Among the nivolumab cohort, 64% were male, with median age of 63 years, 82.3% were smokers, 77% had performance status ≤1 and 63% had adenocarcinoma histology. High-TIL was observed in 22% patients and associated with OS (hazard ratio [HR] 0.48; 95% confidence interval [95% CI]: 0.28-0.81) and progression-free survival [PFS] (HR = 0.40; 95% CI: 0.25-0.64). Median PFS was 13.0 months (95% CI: 5.0-not reached) with high-TIL versus 2.2 months (95% CI: 1.7-3.0) with the presence of a low TIL count (low-TIL). Median OS for high-TIL was not reached (95% CI: 12.2-not reached) versus 8.4 months (95% CI: 5.0-11.6) in the low-TIL group. High-TIL was associated with the overall response rate (ORR) and disease control rate (DCR) (both, P < .0001). Among the chemotherapy cohort, 69% were male, 89% were smokers, 86% had performance status ≤1 and 90% had adenocarcinoma histology. High-TIL was seen in 37%. Median PFS and OS were 5.7 months (95% CI: 4.9-6.7) and 11.7 months (95% CI: 9.3-13.0), respectively, with no association with TILs. CONCLUSIONS: High-TIL was associated with favourable outcomes in a real-world immunotherapy cohort of patients with NSCLC, but not with chemotherapy, suggesting that TILs may be useful in selecting patients for immunotherapy.

Published
2021

10. Multi-strain fermented milk promotes gut microbiota recovery after Helicobacter pylori therapy: a randomised, controlled trial

Author

Guillemard, Eric, primary, Poirel, Marion, additional, Schäfer, Florent, additional, Quinquis, Laurent, additional, Rossoni, Caroline, additional, Keicher, Christian, additional, Wagner, Frank, additional, Szajewska, Hania, additional, Barbut, Frédéric, additional, Derrien, Muriel, additional, and Malfertheiner, Peter, additional

Published
2021
Full Text
View/download PDF

11. Prognostic Clinical and Biologic Features for Overall Survival after Relapse in Childhood Medulloblastoma

Author

Huybrechts, Sophie, primary, Le Teuff, Gwénaël, additional, Tauziède-Espariat, Arnault, additional, Rossoni, Caroline, additional, Chivet, Anaïs, additional, Indersie, Émilie, additional, Varlet, Pascale, additional, Puget, Stéphanie, additional, Abbas, Rachid, additional, Ayrault, Olivier, additional, Guerrini-Rousseau, Léa, additional, Grill, Jacques, additional, Valteau-Couanet, Dominique, additional, and Dufour, Christelle, additional

Published
2020
Full Text
View/download PDF

12. Prospective Multicenter Study Validate a Prediction Model for Surgery Uptake Among Women with Atypical Breast Lesions

Author

Uzan, Catherine, primary, Mazouni, Chafika, additional, Rossoni, Caroline, additional, De Korvin, Brigitte, additional, de Lara, Christine Tunon, additional, Cohen, Monique, additional, Chabbert, Nathalie, additional, Zilberman, Sonia, additional, Boussion, Veronique, additional, Vincent Salomon, Anne, additional, Espie, Marc, additional, Coutant, Charles, additional, Marchal, Frederic, additional, Salviat, Flore, additional, Boulanger, Loic, additional, Doutriaux-Dumoulin, Isabelle, additional, Jouve, Eva, additional, Mathelin, Carole, additional, de Saint hilaire, Pierre, additional, Mollard, Joelle, additional, Balleyguier, Corinne, additional, Joyon, Natacha, additional, Triki, Magali Lacroix, additional, Delaloge, Suzette, additional, and Michiels, Stefan, additional

Published
2020
Full Text
View/download PDF

14. SupplementaryMaterials_PhaseIandII – Supplemental material for Sequential or combined designs for Phase I/II clinical trials? A simulation study

Author

Rossoni, Caroline, Bardet, Aurélie, Geoerger, Birgit, and Paoletti, Xavier

Subjects
congenital, hereditary, and neonatal diseases and abnormalities, FOS: Clinical medicine, 160807 Sociological Methodology and Research Methods, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, FOS: Sociology
Abstract

Supplemental material, SupplementaryMaterials_PhaseIandII for Sequential or combined designs for Phase I/II clinical trials? A simulation study by Caroline Rossoni, Aurélie Bardet, Birgit Geoerger and Xavier Paoletti in Clinical Trials

Published
2019
Full Text
View/download PDF

16. AcSé-ESMART: European Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in Children and Adolescents–Arm D: Olaparib and irinotecan.

Author

Gatz, Susanne Andrea, primary, Rubino, Jonathan, additional, Rossoni, Caroline, additional, Andre, Nicolas, additional, Aerts, Isabelle, additional, Thebaud, Estelle, additional, Nebchi, Souad, additional, Rondof, Windy, additional, Hübschmann, Daniel, additional, Mortimer, Peter G., additional, Paoletti, Xavier, additional, Vassal, Gilles, additional, and Geoerger, Birgit, additional

Published
2019
Full Text
View/download PDF

20. Prognostic Clinical and Biologic Features for Overall Survival after Relapse in Childhood Medulloblastoma.

Author

Huybrechts, Sophie, Le Teuff, Gwénaël, Tauziède-Espariat, Arnault, Rossoni, Caroline, Chivet, Anaïs, Indersie, Émilie, Varlet, Pascale, Puget, Stéphanie, Abbas, Rachid, Ayrault, Olivier, Guerrini-Rousseau, Léa, Grill, Jacques, Valteau-Couanet, Dominique, and Dufour, Christelle

Subjects
SURVIVAL, CONFIDENCE intervals, GLIOMAS, CANCER relapse, RETROSPECTIVE studies, TUMORS in children, DESCRIPTIVE statistics, CHILDREN
Abstract

Simple Summary: Despite progress in the biology and upfront treatment of childhood medulloblastoma, relapse is almost universally fatal. No standardized treatment has so far been established for these patients. By determining which characteristics are prognostic after relapse, treatment strategies may be optimized for each of these children. We demonstrated that molecular subgroup at diagnosis is a relevant prognostic factor of outcome after relapse. Moreover, we showed that time to relapse and the use of salvage radiotherapy at relapse might have a potential impact on post-relapse survival. Our data suggest that ongoing efforts toward a better understanding of the biology, timing and type of relapse would be important to understand the determinants of tumor behavior at relapse. This could help us address more specific questions on the best surveillance strategies after completion of the treatment and the introduction of risk-stratified second-line treatment strategies. Given the very poor prognosis for children with recurrent medulloblastoma, we aimed to identify prognostic factors for survival post-relapse in children with childhood medulloblastoma. We retrospectively collected clinico-biological data at diagnosis and main clinical characteristics at relapse of children newly diagnosed with a medulloblastoma between 2007 and 2017 at Gustave Roussy and Necker Hospital. At a median follow-up of 6.6 years (range, 0.4–12.3 years), relapse occurred in 48 out 155 patients (31%). The median time from diagnosis to relapse was 14.3 months (range, 1.2–87.2 months). Relapse was local in 9, metastatic in 22 and combined (local and metastatic) in 17 patients. Second-line treatment consisted of chemotherapy in 31 cases, radiotherapy in 9, SHH-inhibitor in four and no treatment in the remaining four. The 1-year overall survival rate post-relapse was 44.8% (CI 95%, 31.5% to 59.0%). While molecular subgrouping at diagnosis was significantly associated with survival post-relapse, the use of radiotherapy at relapse and time to first relapse (>12 months) might also have a potential impact on post-relapse survival. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results